Browsing Clinical Studies by author "Seed, George"
Now showing items 1-20 of 22
-
Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors.
Neeb, A; Herranz, N; Arce-Gallego, S; Miranda, S; Buroni, L; et al. (ELSEVIER, 2020-11-08)BACKGROUND: Deleterious ATM alterations are found in metastatic prostate cancer (PC); PARP inhibition has antitumour activity against this subset, but only some ATM loss PCs respond. OBJECTIVE: To characterise ATM-deficient ... -
Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer.
Sharp, A; Coleman, I; Yuan, W; Sprenger, C; Dolling, D; et al. (AMER SOC CLINICAL INVESTIGATION INC, 2019-01-02)BACKGROUND: Liquid biopsies have demonstrated that the constitutively active androgen receptor splice variant-7 (AR-V7) associates with reduced response and overall survival from endocrine therapies in castration-resistant ... -
Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial.
Carreira, S; Porta, N; Arce-Gallego, S; Seed, G; Llop-Guevara, A; et al. (AMER ASSOC CANCER RESEARCH, 2021-11-01)PARP inhibitors are approved for treating advanced prostate cancers (APC) with various defective DNA repair genes; however, further studies to clinically qualify predictive biomarkers are warranted. Herein we analyzed ... -
CD38 in Advanced Prostate Cancers.
Guo, C; Crespo, M; Gurel, B; Dolling, D; Rekowski, J; et al. (ELSEVIER, 2021-05-13)BACKGROUND: CD38, a druggable ectoenzyme, is involved in the generation of adenosine, which is implicated in tumour immune evasion. Its expression and role in prostate tumour-infiltrating immune cells (TIICs) have not been ... -
Characterizing CDK12-Mutated Prostate Cancers.
Rescigno, P; Gurel, B; Pereira, R; Crespo, M; Rekowski, J; et al. (AMER ASSOC CANCER RESEARCH, 2020-09-28)PURPOSE: Cyclin-dependent kinase 12 (CDK12) aberrations have been reported as a biomarker of response to immunotherapy for metastatic castration-resistant prostate cancer (mCRPC). Herein, we characterize CDK12-mutated ... -
Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition.
Goodall, J; Mateo, J; Yuan, W; Mossop, H; Porta, N; et al. (AMER ASSOC CANCER RESEARCH, 2017-09-01)Biomarkers for more precise patient care are needed in metastatic prostate cancer. We have reported a phase II trial (TOPARP-A) of the PARP inhibitor olaparib in metastatic prostate cancer, demonstrating antitumor activity ... -
Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC counts.
Lorente, D; Olmos, D; Mateo, J; Dolling, D; Bianchini, D; et al. (ELSEVIER, 2018-07-01)BACKGROUND: The development of treatment response and surrogate biomarkers for advanced prostate cancer care is an unmet clinical need. Patients with baseline circulating tumour cell (BLCTCs) counts <5/7.5 mL represent a ... -
Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer.
Sharp, A; Welti, JC; Lambros, MBK; Dolling, D; Rodrigues, DN; et al. (ELSEVIER, 2019-11-01)BACKGROUND: Detection of androgen receptor splice variant-7 (AR-V7) mRNA in circulating tumour cells (CTCs) is associated with worse outcome in metastatic castration-resistant prostate cancer (mCRPC). However, studies ... -
Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer.
Lorente, D; Olmos, D; Mateo, J; Bianchini, D; Seed, G; et al. (ELSEVIER SCIENCE BV, 2016-12-01)BACKGROUND: Treatment response biomarkers are urgently needed for castration-resistant prostate cancer (CRPC). Baseline and post-treatment circulating tumor cell (CTC) counts of ≥5 cells/7.5ml are associated with poor CRPC ... -
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.
Mateo, J; Carreira, S; Sandhu, S; Miranda, S; Mossop, H; et al. (MASSACHUSETTS MEDICAL SOC, 2015-10-29)BACKGROUND: Prostate cancer is a heterogeneous disease, but current treatments are not based on molecular stratification. We hypothesized that metastatic, castration-resistant prostate cancers with DNA-repair defects would ... -
Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNA.
Sumanasuriya, S; Seed, G; Parr, H; Christova, R; Pope, L; et al. (ELSEVIER, 2021-08-01)BACKGROUND: Better blood tests to elucidate the behaviour of metastatic castration-resistant prostate cancer (mCRPC) are urgently needed to drive therapeutic decisions. Plasma cell-free DNA (cfDNA) comprises normal and ... -
Gene Copy Number Estimation from Targeted Next-Generation Sequencing of Prostate Cancer Biopsies: Analytic Validation and Clinical Qualification.
Seed, G; Yuan, W; Mateo, J; Carreira, S; Bertan, C; et al. (AMER ASSOC CANCER RESEARCH, 2017-10-15)Purpose: Precise detection of copy number aberrations (CNA) from tumor biopsies is critically important to the treatment of metastatic prostate cancer. The use of targeted panel next-generation sequencing (NGS) is inexpensive, ... -
Genomics of lethal prostate cancer at diagnosis and castration resistance.
Mateo, J; Seed, G; Bertan, C; Rescigno, P; Dolling, D; et al. (AMER SOC CLINICAL INVESTIGATION INC, 2020-04-01)The genomics of primary prostate cancer differ from those of metastatic castration-resistant prostate cancer (mCRPC). We studied genomic aberrations in primary prostate cancer biopsies from patients who developed mCRPC, ... -
Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer.
Nava Rodrigues, D; Rescigno, P; Liu, D; Yuan, W; Carreira, S; et al. (AMER SOC CLINICAL INVESTIGATION INC, 2018-10-01)BACKGROUND: Understanding the integrated immunogenomic landscape of advanced prostate cancer (APC) could impact stratified treatment selection. METHODS: Defective mismatch repair (dMMR) status was determined by either loss ... -
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial.
Mateo, J; Porta, N; Bianchini, D; McGovern, U; Elliott, T; et al. (ELSEVIER SCIENCE INC, 2020-01-01)BACKGROUND: Metastatic castration-resistant prostate cancer is enriched in DNA damage response (DDR) gene aberrations. The TOPARP-B trial aims to prospectively validate the association between DDR gene aberrations and ... -
Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA).
Mehra, N; Dolling, D; Sumanasuriya, S; Christova, R; Pope, L; et al. (ELSEVIER, 2018-09-01)BACKGROUND: Noninvasive biomarkers are needed to guide metastatic castration-resistant prostate cancer (mCRPC) treatment. OBJECTIVE: To clinically qualify baseline and on-treatment cell-free DNA (cfDNA) concentrations as ... -
Precision genomics for prostate cancer patient stratification
de Bono, J; Seed, G (Institute of Cancer Research (University Of London), 2020-10-31)Introduction Several unmet needs currently persist in advanced prostate cancers. Despite recent discoveries, such as identification of deficient DNA repair pathways as a key driver of prostate tumour development, relatively ... -
Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer.
Paschalis, A; Sheehan, B; Riisnaes, R; Rodrigues, DN; Gurel, B; et al. (ELSEVIER, 2019-10-01)BACKGROUND: Prostate-specific membrane antigen (PSMA; folate hydrolase) prostate cancer (PC) expression has theranostic utility. OBJECTIVE: To elucidate PC PSMA expression and associate this with defective DNA damage repair ... -
Second-Generation HSP90 Inhibitor Onalespib Blocks mRNA Splicing of Androgen Receptor Variant 7 in Prostate Cancer Cells.
Ferraldeschi, R; Welti, J; Powers, MV; Yuan, W; Smyth, T; et al. (AMER ASSOC CANCER RESEARCH, 2016-05-01)Resistance to available hormone therapies in prostate cancer has been associated with alternative splicing of androgen receptor (AR) and specifically, the expression of truncated and constitutively active AR variant 7 ... -
Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by Apheresis.
Lambros, MB; Seed, G; Sumanasuriya, S; Gil, V; Crespo, M; et al. (AMER ASSOC CANCER RESEARCH, 2018-11-15)Purpose: Circulating tumor cells (CTCs) have clinical relevance, but their study has been limited by their low frequency.Experimental Design: We evaluated liquid biopsies by apheresis to increase CTC yield from patients ...